Journals / Medical Network Klinik Bilimler ve Doktor / 2005 / Cilt: 11 - Sayı: 5

Griscelli syndrome with Hodgkin lymphoma: A case report

Hodgkin lenfoma tanısı alan griscelli sendromlu bir olgu

Pages
515–519
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was found interesting association with GS and lymphoma in our children and this case is presented here.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Griscelli Syndrome (GS) is a rare autosomal recessive disorder that results in pigmentary dilution of the skin and the hair (silver hair), and associated various degree of immunodeficiency.
📊
Key Findings & Data:Griscelli Syndrome usually manifests in persons aged 1 month to 8 years.
💡
Conclusion & Impact:It was found interesting association with GS and lymphoma in our children and this case is presented here.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Lenfom · Pigmentasyon bozuklukları · Hodgkin hastalığı

Abstract

Griscelli Syndrome (GS) is a rare autosomal recessive disorder that results in pigmentary dilution of the skin and the hair (silver hair), and associated various degree of immunodeficiency. Griscelli Syndrome usually manifests in persons aged 1 month to 8 years. Recurrent fever episodes and infections, hepatosplenomegaly, lymphadenomegaly caused by hemophagositic lymphohistiocytosis, and neurologic deficities may be seen the course of the disease. Three subtype of the disease were defined three subtype such as gene mutations of RAB27A and MYO5A that are located at band 15q21 and MLPH gene mutation located at band 2q37. Type 1 GS is caused by RAB27A gene mutation and among these cases hepatosplenomegaly, lymphohistiocytosis, combined T and B deficiencies are prominent. Naturel killer cell dysfunction may be found. In this mutation no reaction of delayed type hypersensitivity, poor proliferation to antigenic stimulus is detected but low levels of immunoglobulins may rarely determined. In type 2 GS caused by MYO5A gene mutation neurologic menifestations are more prominent. In type 3 GS caused by MPLH gene mutation no prominent finding except characteristic hypopigmentation. Although it is known predisposition to risk of developing malignancy in immunodeficient children, there was no report obtained associated with GS and malignancy. It was found interesting association with GS and lymphoma in our children and this case is presented here.

Özet

Griscelli Sendromu (GS) otosomal resesif geçişli, saçta ve deride pigmentasyon azlığı (gümüş grisi saçlar ) ile değişik derecelerde immün yetersizliğin bir arada bulunduğu bir hastalıktır. Hastaların çoğu 1 ay ile 8 yaş arasında tanı almaktadır. Hastalığın seyri sırasında tekrarlayan ateş ve enfeksiyon atakları, hemofagositik lenfohistiositoza bağlı lenfadenomegali, hepatosplenomegali, değişik derecelerde nörolojik defisitler görülebilmektedir. Hastalığın; 15q21 bölgesinde yer alan RAB27A, MYO5A ve diğeri 2q37 bölgesinde bulunan MLPH gen mutasyonlarına bağlı üç alt tipi tanımlanmıştır. RAB27A mutasyonu saptanan Griscelli sendromlu olgular Tip1 (GS1) olarak ismlendirilir ve bu hastalarda hepatosplenomegali, lenfohistiositoz, kombine T ve B hücre yetersizlikleri belirgindir. NK hücrelerinde fonksiyon bozukluğu olabilir. Bu mutasyonda geç tipte hipersensitivite reaksiyonu yoktur ve antijenik uyarana lenfositlerin zayıf proliferasyonu görülmektedir. Beraberinde nadiren immünglobulin düzeylerinde düşüklük de olabilmektedir. Hastalığın MYO5A mutasyonuna bağlı olan 2. tipinde (GS2), nörolojik bulgular daha belirgindir. MPLH gen mutasyonunu görülen tip 3'de (GS3) ise karakteristik hipopigmentasyon dışında klinik bulgu yoktur. İmmün yetersizliklerde, malignite gelişimine yatkınlık olduğunun bilinmesine rağmen, literatürde Griscelli Sendromu ve malignite birlikteliği saptanamamıştır. Griscelli Sendromu tanısı alan olgumuzda aynı zamanda Hodgkin Lenfoma da saptanması nedeniyle ilginç bulunarak sunulmuştur.

🔖

Cite This Article

KAYSERİLİ, E., APA, H., GÜLEZ, P., HIZARCIKLIOĞLU, M., YILMAZ, Ö., DİNİZ, A. G., AKTAŞ, S. (2005). Griscelli syndrome with Hodgkin lymphoma: A case report. Medical Network Klinik Bilimler ve Doktor, Cilt: 11 - Sayı: 5, 515–519. https://ajindex.com/articles/278449

References (1)

  1. Griscelli C, Durandy A, Guy-Grand D, Daguillard F, Herzog Prunieras M. A syndrome associating partial albinism and munodeficiency. Am J Med 1978; 65:691-702. 2-Haraldsson A, Weemas CMR, Bakarken JAJM, Happle R.iscelli disease with cerebral involvement. Eur. J. Pediatr 1991;0:419-22. 3-.Korman LY, Smith JR, Landaw SA, Davey FIR. Hodgkin's Disease: intramedullary phagocytosis with pancytopenia. Ann Intern Med 1979; 91:60-1. 4.Chim C S, Hui P K. Reactive hemophagocytic syndrome and Hodgkin's disease. Amer J Hematol 1997; 55:49-54. 5.Hudson MM., Donaldson SS. Hodgkin's disease. In: Pizzo A P, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippmcott Williams&Wilkins 2002: 637-42. 6.Barak Y, Nir E. Chediak-Higashi syndrome. Am J Pediatr Hematol Oncol 1987; 9:42-55.7. 7.Sheela S R, Latha M, Susy J I. Griscelli sydrome: Rab 27a mutation. Indian Pediatr 2004; 41:944-7. 8.Mancini AJ, Chan LS, Paller AS. Partial albinism with immunodeficiency. Griscelli Syndrome. Report of a case and review of the literature. J Am Dermatol 1998; 38:295-300. 9.Noah S Scheinfeld, FAAD JD. Griscelli Syndrome.Emedicine-2004. 10.Sanal Ö, Ersoy F, Tezcan İ, et al. Genevie/ve De Saint Basile. Griscelli disease: genotype-phenotype correlation in anarray of clinical heterogeneity. J Clin Immunol 2002; 22:237-43. 11.KIuin-Nelemans JC, Kluin PM, Bieger R. A 26-year-old man with Hodgkin's disease and rapidly progressive pancytopenia. Ann Hematoi 1993; 67:49-56. 12.Çavdar A.O, Pamir A. Et al. Hodgkin's disease in children:Clinicoepidemiologic and viral (Epstein-Barr virus) analyses. Med. Ped. Oncol 1999; 32:18-24. 13.Çavdar A.O, Gözdaşoğlu S et al. Early type-1 pattern (0-6 years) Hodgin's disease in Turkish children. Turk.J.Haematol 2002; 19:55-62.